Table 1 List of the clinical trials with microtubule targeting agents on HGBT patients.
From: Inhibiting microcephaly genes as alternative to microtubule targeting agents to treat brain tumors
Compound | Disease | Stage of clinical development | Results | Side effects | References |
|---|---|---|---|---|---|
Paclitaxel | Astrocytoma, Malignant glioma, Medulloblastoma, Brain stem glioma, Ependymoma | Phase II | Paclitaxel resulted in complete or partial response rate in 5.7% of the patients and stable disease in 14% of the patients. It can be administered with radiotherapy | Hematologic toxicity, febrile neutropenia, nausea and vomiting | |
Docetaxel | Astrocytoma, Glioma, Medulloblastoma, Brain stem glioma, Ependymoma | Phase II | Docetaxel was tolerated well but poor effective for treating these types of recurrent solid tumors | Hematologic toxicity and liver and gastrointestinal toxicity in some patients | [20] |
Vincristine | Astrocytoma, Oligoastrocytoma, Oligodendroglioma, Glioblastoma | Phase II/III | Combination chemotherapy with Vincristine in addition to radiation therapy resulted in longer overall survival compared to radiation alone | Hematologic toxicity, fatigue, anorexia, nausea, vomiting | |
Patupilone (Epothilone B) | Glioblastoma | Phase I/II | Epothilone B was well tolerated and progression free at 6 months was observed in 22% of the patients. It can be administered with radiotherapy | Reversible sensory neuropathy, diarrhea, nausea and vomiting | |
Sagopilone | Gliosarcoma, glioblastoma multiforme, anaplastic astrocytoma | Phase II | Progression free at 6 months was observed in 33% of the patients | Peripheral neuropathy, hematologic toxicity |
